Medicure Inc. (OTCMKTS:MCUJF) Shares Shorted: Short Interest Up 396.1% in October

Medicure Inc. (OTCMKTS:MCUJF) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 16,610 shares, a growth of 396.1% from the October 15th total of 3,348 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average trading volume of 29,975 shares, the days-to-cover ratio is currently 0.6 days.

Medicure Trading Up 1.1%

Shares of MCUJF stock traded up $0.03 during trading hours on Wednesday, reaching $2.64. 5,480 shares of the stock traded hands, compared to its average volume of 12,584. The company has a quick ratio of 0.64, a current ratio of 0.97 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $27.72 million, a PE ratio of -5.18 and a beta of 1.10. Medicure has a 1-year low of $0.67 and a 1-year high of $3.45. The business has a fifty day moving average price of $2.36 and a 200 day moving average price of $1.22.

Medicure (OTCMKTS:MCUJF) last released its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Medicure had a negative net margin of 23.14% and a negative return on equity of 54.55%. The business had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $2.45 million.

Medicure Company Profile

Medicure Inc. is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations. Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.